Sublingual Omp16-driven redirection of the allergic intestinal response in a pre-clinical model of food allergy

ORSINI DELGADO, MARIA LUCÍA; PASQUEVICH, KARINA ALEJANDRA; DOCENA, GUILLERMO HORACIO; RIZZO, GASTÓN PASCUAL; CASSATARO, JULIANA; FOSSATI, CARLOS ALBERTO; SMALDINI, PAOLA LORENA

CLINICAL AND EXPERIMENTAL ALLERGY

WILEY-BLACKWELL PUBLISHING, INC

Año: 2020 vol. 50 p. 954 - 963

0954-7894

Background: IgE-mediated food allergy remains a significant and growing worldwide problem. Sublingual immunotherapy (SLIT) shows an excellent safety profile for food allergy, but the clinical efficacy needs to be improved. This study assessed the effects of the Toll-like receptor 4 agonist outer membrane protein (Omp) 16 from Brucella abortus combined with cow´s milk proteins (CMP) through the sublingual route to modulate cow´s milk allergy in an experimental model.Methods: Mice sensitized with cholera toxin and CMP were orally challenged with the allergen to elicit hypersensitivity reactions. Then, mice were treated with a very low amount of CMP along with Omp16 as a mucosal adjuvant, and finally, animals were re-exposed to CMP. Systemic and mucosal immune parameters were assessed in vivo and in vitro.Results: We found that the sublingual administration of Omp16+CMP induced a buccal Th1-immune response that modulated the intestinal allergic response with the suppression of symptoms, reduction of IgE and IL-5, and up-regulation of IgG2a and IFN-γ. The adoptive transfer of submandibular IFN-γ-producing α4β7+ CD4+ and CD8+ cells conferred protection against allergic sensitization. The use of Omp16+CMP promoted enhanced protection compared to CMP alone.Conclusion: In conclusion, Omp16 represents a promising mucosal adjuvant that can be used to improve the clinical and immune efficacy of SLIT for food allergy.Keywords: Food allergy; IgE; Mouse model; Omp16; Sublingual immunotherapy.